We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03281824
Recruitment Status : Completed
First Posted : September 13, 2017
Last Update Posted : January 18, 2022
Information provided by (Responsible Party):
Alteogen, Inc.

Brief Summary:
This open-label study assessed the safety, tolerability and pharmacokinetics of ALT-P7(HM2-Drug Conjugate) in patients with HER2-positive metastatic breast cancer who have progressed on previous Trastuzumab-based therapy. Patients received ALT-P7(0.3 mg/kg~5.4 mg/kg, 7 groups) intravenously on Day 1 of each 3-week cycle.

Condition or disease Intervention/treatment Phase
HER2-positive Breast Cancer Biological: ALT-P7 (HM2-MMAE) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Open-Label, Dose Increase and Phase I Study of ALT-P7 to Determine Safety, Tolerability, Pharmacokinetics for HER2 Positive Metastatic Breast Cancer Patients Who Have Progressed on Previous Trastuzumab-Based Therapy
Actual Study Start Date : January 11, 2018
Actual Primary Completion Date : March 12, 2020
Actual Study Completion Date : January 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: ALT-P7
  • 8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,
  • Administration: Day 1 of each 3-week cycle
Biological: ALT-P7 (HM2-MMAE)
Antibody-Drug Conjugate

Primary Outcome Measures :
  1. DLT test [ Time Frame: 21 days after first administration ]
    Determination of Maximum Tolerated Dose(MTD) and the dose level showing Dose Limiting Toxicity(DLT), or determination of Recommended Phase II Dose(RP2D) as an alternative to MTD establishment

Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: up to 4 weeks ]
    Evaluate adverse events by the Common Terminology Criteria for Adverse Event (CTCAE v4.03) classification, immune-related adverse events(irAEs)

  2. Pharmacokinetics test [ Time Frame: up to 4 weeks ]
    analyze metabolism and discover the fate of a ALT-P7 from administration up to completely eliminated from the body (Group 3(1.2 mg/kg) ~ Group 7(5.4 mg/kg))

  3. Immunogenicity test [ Time Frame: up to 4 weeks ]
    After administration of the drug for clinical trial, the descriptive statistics of the dose group and the measurement point are calculated

  4. Efficacy test [ Time Frame: At the end of Cycle 2 (each cycle is 21 days) ]
    Provide descriptive statistics for each capacity group(the number of subjects, average, standard deviation, median, minimum value, maximum value)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient who voluntarily signed the agreement
  2. Adult patients ≥ 19 years of age
  3. Eastern Cooperative Oncology Group(ECOG) Performance status of 0 or 1
  4. Appropriate organism function proven by the following laboratory test results

    • Absolute neutrophil count ≥ 1500 cells/mm³
    • Platelets ≥ 100,000 cells/mm³
    • Hemoglobin ≥ 9.0 g/dL

      • Patients can receive red blood cell transfusions at this level.
    • Creatinine ≤ 1.5 × Upper Limit of Normal(ULN)
    • Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤ 2.5 × ULN
    • Alkaline phosphatase ≤ 2.5 × ULN

      • Patients with liver and/or bone metastases: AST and ALT ≤ 5 × ULN, Alkaline phosphatase ≤ 5 × ULN
    • Albumin ≥ 3.0 g/dL, Total bilirubin ≤ 2.0 mg/dL
    • International Normalized Ratio(INR) < 1.5 × ULN(Except when you are on therapeutic anticoagulation therapy)
  5. It should be negative in serum pregnancy test in the case of pre-menopausal women and women who were menopausal for less than 12 months
  6. In the case of a fertile woman, it should be negative in pregnancy test, and all men and women should use effective contraceptive methods while enrolled in this study. You must also agree to continue the contraception during the trial and up to 6 months after the last dose of the test
  7. Those who are expected to understand and observe the clinical trial plan according to the tester's judgment
  8. Those who voluntarily agreed to participate in this clinical trial and signed the agreement

Exclusion Criteria:

  • Criteria for disease

    1. Previous history of intolerance to Trastuzumab including Grade 3-4 infusion reaction or hypersensitivity
    2. Previous history of permanent discontinuation of Trastuzumab due to the toxicity
    3. A person who has untreated or symptomatic brain metastasis, or brain metastasis requiring radiation, surgery or corticosteroid therapy to control the brain metastases within 4 weeks of the first administration
    4. Current Grade ≥ 2 (according to National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events(CTCAE) v4.03 of peripheral neuropathy
    5. If the toxicity of the previous treatment is not recovered to baseline level or lower than Grade 1 except for hair loss and peripheral neuropathy
    6. Hypercalcemia requiring bisphosphonate therapy (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) However, it is allowed if bisphosphonate has been used for bone metastasis
    7. A person who has received clinical trial material, chemotherapy, hormone therapy, radiotherapy, immunotherapy or biological therapy within 3 weeks of the first administration. However, it is required a minimum of 2 weeks after surgery if stereotactic radiosurgery is performed
    8. Previous history of exposure to the cumulative dose of anthracycline (Doxorubicin > 360 mg/m², Epirubicin > 600 mg/m²)
  • Criteria for cardio pulmonary function

    1. Unstable ventricular arrhythmia requiring treatment
    2. Previous history of symptomatic congestive heart failure (NYHA Class II-IV)
    3. Previous history of myocardial infarction or unstable angina within 6 months
    4. Cardiac troponin I ≥ 0.2 ng/mL
    5. A person who has inadequate left ventricular ejection fraction(LVEF) within 3 weeks of the first administration, LVEF <50% by echocardiography or Multiple-gated Acquisition(MUGA)
    6. A person who has severe dyspnea or pneumonia requiring continuous oxygen therapy
  • Common criteria

    1. Pregnant or breastfeeding
    2. A person who has undergone surgical operation or significant traumatic injury within 30 days before registration, or is expected to require surgical operation during the clinical trial
    3. Previous history of malignant tumors other than breast cancer within 5 years prior to screening (patient who can participate: squamous cell and basal cell carcinoma of the skin, intraepithelial cancer of the cervix, thyroid papillary cancer, or if the tester considers that the risk of relapse is minimum(regard as full recovery) and the sponsor agrees with it)
    4. A person who needs chronic corticosteroid therapy (≥ 10 mg/day prednisone or equivalent volume of other anti-inflammatory corticosteroids)
    5. If the result of human immunodeficiency virus (HIV), active hepatitis B or hepatitis C is positive during screening
    6. Patients with uncontrolled concomitant illnesses, including mental illness/social conditions, which may affect compliance with clinical trial procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03281824

Layout table for location information
Korea, Republic of
Daejeon, Korea, Republic of
Sponsors and Collaborators
Alteogen, Inc.
Layout table for additonal information
Responsible Party: Alteogen, Inc.
ClinicalTrials.gov Identifier: NCT03281824    
Other Study ID Numbers: ALT-P7
First Posted: September 13, 2017    Key Record Dates
Last Update Posted: January 18, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alteogen, Inc.:
HER2 Positive Breast Cancer
Antibody-Drug Conjugate
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases